⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12959747 | 0.82 | — | — | |
| SCHEMBL19731425 | 0.82 | — | — | |
| Fluoride SCHEMBL7237073 | 0.79 | — | — | |
| SCHEMBL6899229 | 0.75 | — | — | |
| SCHEMBL101748 | 0.69 | — | — | |
| SCHEMBL24385392 | 0.69 | — | — | |
| SCHEMBL15082706 | 0.69 | — | — | |
| SCHEMBL25268925 | 0.69 | CHRM2 (0.31) | — | |
| SCHEMBL559869 | 0.69 | — | — | |
| SCHEMBL984153 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240398784-A1 | C-LINKED ISOQUINOLINE AMIDES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2024-12-05 | — | — | US | disclosed |
| EP-4408427-A1 | SYSTEM AND METHOD FOR STATIC AND DYNAMIC MRI SHIMMING | Merck Sharp & Dohme LLC (US) | 2024-08-07 | — | — | EP | disclosed |
| CN-114369094-B | Trifluoromethyl substituted sulfonamide selective BCL-2 inhibitors | 正大天晴药业集团股份有限公司 | 2023-09-29 | — | — | CN | disclosed |
| US-20230192671-A1 | COMPOUNDS FOR THE TREATMENT OF SARS | PURDUE RESEARCH FOUNDATION | 2023-06-22 | — | — | US | disclosed |
| WO-2023055679-A1 | C-LINKED ISOQUINOLINE AMIDES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2023-04-06 | — | — | WO | disclosed |
| CN-114369094-A | Trifluoromethyl substituted sulfonamide selective BCL-2 inhibitors | 正大天晴药业集团股份有限公司 | 2022-04-19 | — | — | CN | disclosed |
| WO-2021254384-A1 | NOVEL PYRIDO[2,3-D]PYRIMIDINE-7(8H)-ONE DERIVATIVE | 微境生物医药科技(上海)有限公司 | 2021-12-23 | — | — | WO | disclosed |
| CN-111868059-B | Trifluoromethyl substituted sulfonamide selective BCL-2 inhibitors | 正大天晴药业集团股份有限公司 | 2021-12-03 | — | — | CN | disclosed |
| CN-111868059-A | Trifluoromethyl substituted sulfonamide selective BCL-2 inhibitors | 正大天晴药业集团股份有限公司 | 2020-10-30 | — | — | CN | disclosed |
| US-10752609-B2 | GSK-3 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-08-25 | — | — | US | disclosed |
| US-20080255113-A1 | Quinolonecarboxylic Acid Compounds Having 5-Ht4 Receptor Agonistic Activity | KATO TOMOKI | 2008-10-16 | — | — | US | disclosed |
| US-20080255113-A1 | Quinolonecarboxylic Acid Compounds Having 5-Ht4 Receptor Agonistic Activity | KATO TOMOKI | 2008-10-16 | — | — | US | disclosed |
| US-20080255113-A1 | Quinolonecarboxylic Acid Compounds Having 5-Ht4 Receptor Agonistic Activity | KATO TOMOKI | 2008-10-16 | — | — | US | disclosed |
| EP-1857455-A1 | CINNAMOYL COMPOUND AND USE THEREOF | Sumitomo Chemical Company, Limited (JP) | 2007-11-21 | — | — | EP | disclosed |
| EP-1857104-A1 | USE OF CINNAMOYL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2007-11-21 | — | — | EP | disclosed |
| US-20070265228-A1 | Cinnamoyl compound and use of the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-11-15 | — | — | US | disclosed |
| US-20070265228-A1 | Cinnamoyl compound and use of the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-11-15 | — | — | US | disclosed |
| EP-1689742-A1 | QUINOLONECARBOXYLIC ACID COMPOUNDS HAVING 5-HT4 RECEPTOR AGONISTIC ACTIVITY | Pfizer, Inc. (US) | 2006-08-16 | — | — | EP | disclosed |
| WO-2005049608-A1 | QUINOLONECARBOXYLIC ACID COMPOUNDS HAVING 5-HT4 RECEPTOR AGONISTIC ACTIVITY | PFIZER JAPAN, INC. (JP) | 2005-06-02 | — | — | WO | disclosed |
| WO-2005049608-A1 | QUINOLONECARBOXYLIC ACID COMPOUNDS HAVING 5-HT4 RECEPTOR AGONISTIC ACTIVITY | PFIZER JAPAN, INC. (JP) | 2005-06-02 | — | — | WO | disclosed |